Correction: In the Prostate Cancer CPD article in the February issue of Australian Pharmacist, a production error caused ADT to be incorrectly defined. ADT is androgen deprivation therapy.

Mr Jones, 87, was diagnosed with metastatic prostate cancer 12 months ago and was commenced on goserelin and bicalutamide. He completed 6 cycles of docetaxel 6 months ago. During a routine follow-up scan, bony metastases were evident, accompanied by a rising level of prostate specific antigen. Mr Jones is currently taking goserelin, bicalutamide, calcium and vitamin D, and paracetamol when required. He has no other medical history and does not take any other medicines.

Learning objectives

After successful completion of this CPD activity, pharmacists should be able to:

  • Recognise the risk factors for prostate cancer
  • Discuss the diagnosis of prostate cancer
  • Recognise the role of the pharmacist in managing a patient with prostate cancer.

Competency standards (2016) addressed: 1.1, 1.3, 1.4, 2.1, 2.3, 2.4, 3.2

Already read the CPD in the journal? Scroll to the bottom to SUBMIT ANSWERS.

Introduction

In Australia, prostate cancer is the most commonly diagnosed cancer in men.1 Although the exact pathogenesis is not completely understood, prostate cancer arises from mutations and unchecked proliferation (cell growth).2 Prevalence increases with age; with an aging population in Australia, the incidence is expected to rise.1 Current treatment options are largely based on the work of Dr Charles Huggins in the 1940s. His discovery of the relationship between the male sex hormone and the disease course of prostate cancer won him the Nobel Prize in Medicine.

THIS IS A CPD ARTICLE. YOU NEED TO BE A PSA MEMBER AND LOGGED IN TO READ MORE.